This site is intended for Healthcare professionals only.

Lupin gets FDA approval for Doxercalciferol Injection


Lupin gets FDA approval for Doxercalciferol Injection

New Delhi: Pharma major Lupin announced that it has received approval for its Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials from the United States Food and Drug Administration (FDA) to market a generic version of Sanofi Genzyme’s Hectorol Injection.

Lupin’s Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vial is the generic version of Genzyme’s Hectorol Injection. It is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials had annual sales of approximately USD 133 million in the US (IQVIA MAT September 2018).

Read Also: Lupin recalls 6,752 bottles of Testosterone topical solution from US

 



Source: self
0 comment(s) on Lupin gets FDA approval for Doxercalciferol Injection

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted